<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DEXRAZOXANE</span><br/>(dex-ra-zox'ane)<br/><span class="topboxtradename">Zinecard<br/></span><b>Classifications:</b> <span class="classification">chelating agent</span>; <span class="classification">cardioprotective for doxorubicin</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg vials for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Drug is a derivative of EDTA that readily penetrates cell membranes. The mechanism by which dexrazoxane exerts its cardioprotective
         activity is not fully understood.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Dexrazoxane is converted intracellularly to a chelating agent that interferes with iron-mediated free radical generation thought
         to be partially responsible for one form of cardiomyopathy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Reduction of the incidence and severity of cardiomyopathy associated with doxorubicin in women with metastatic breast cancer
         who have received a cumulative doxorubicin dose of 300 mg/m<sup>2</sup>.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Chemotherapy regimens that do not contain anthracycline, lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Myelosuppression, pregnancy (category C). Safety and efficacy in children have not been established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cardiomyopathy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 10 parts dexrazoxane to 1 part doxorubicin or 500 mg/m<sup>2</sup> for every 50 mg/m<sup>2</sup> of doxorubicin, repeated q3wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Wear gloves when handling dexrazoxane. Immediately wash with soap and water if drug contacts skin or mucosa.</li>
<li>Doxorubicin dose MUST be started within 30 min of beginning dexrazoxane.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute by adding 25 or 50 mL of 0.167 M sodium lactate injection (provided by manufacturer) to the 250- or 500-mg vial,
                  respectively, to produce a 10-mg/mL solution.  <span class="methodtype">IV Infusion:</span> Further dilute with NS or D5W in an IV bag to a concentration of 1.35.0 mg/mL for infusion.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Give slow IV push.  <span class="methodtype"> IV Infusion:</span> Give over 10 min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solutions for 6 h at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">All:</span> Adverse effects of dexrazoxane are difficult to distinguish from those of the chemotherapeutic agents. Pain at injection site,
      <span class="speceff-life">leukopenia, granulocytopenia</span>, and <span class="speceff-life">thrombocytopenia</span> appear to occur more frequently with the addition of dexrazoxane than with placebo. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Not bound to plasma proteins. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 42% excreted in urine. <span class="typehead">Half-Life:</span> 22.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiac function. Drug does not eliminate risk of doxorubicin cardiotoxicity.</li>
<li>Lab tests: Monitor hepatic, renal, and hematopoietic status throughout course of therapy.</li>
<li> 								Note: Adverse effects are likely due to concurrent cytotoxic drugs rather than dexrazoxane. 							</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to physician: Worsening shortness of breath, swelling extremities, or chest pains.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>